Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study

作者
Qingyuan Zhang,Pin Zhang,Min Yan,Xi Yan,Xian Wang,Yuanting Gu,Xiujuan Qu,Shaorong Li,Guoying Xu,Xiaoyu Zhu,Binghe Xu
出处
期刊:Therapeutic Advances in Medical Oncology [SAGE Publishing]
卷期号:16: 17588359241273026-17588359241273026 被引量:1
标识
DOI:10.1177/17588359241273026
摘要

Background: Dalpiciclib is a novel cyclin-dependent kinase 4/6 inhibitor which showed tolerability and preliminary efficacy as monotherapy for pretreated advanced breast cancer (BC). Objectives: To further assess dalpiciclib with endocrine therapy (ET) in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative BC. Design: A multicenter, open-label, phase Ib trial. Methods: Patients with locally recurrent or metastatic BC were enrolled in five cohorts. Patients without prior treatment for advanced disease (cohorts 1-2) were given dalpiciclib (125 or 150 mg) plus letrozole/anastrozole; patients who progressed after ET (cohorts 3-5) were given dalpiciclib (125, 150, or 175 mg) plus fulvestrant. Dalpiciclib was administered orally once daily in 3-weeks-on/1-week off schedule. The primary endpoint was safety. Results: A total of 58 patients received dalpiciclib with letrozole/anastrozole and 46 received dalpiciclib with fulvestrant. No maximum tolerated dose of dalpiciclib was reached with letrozole/anastrozole or fulvestrant. Across all cohorts, 86.7%-93.8% of patients had a grade ⩾3 adverse event, with the most common being neutropenia (grade 3, 40.0% for dalpiciclib 175 mg and 61.8%-87.5% for lower doses; grade 4, 46.7% and 4.2%-20.6%, respectively) and leukopenia (grade 3, 80.0% for 175 mg and 33.3%-54.2% for lower doses; grade 4, 0% for all doses). At tested dose levels, steady-state areas under the concentration curve and peak concentration of dalpiciclib increased with dose when combined with letrozole/anastrozole and fulvestrant. Dalpiciclib at 150 mg was associated with a numerically higher objective response rate in both patients untreated for advanced disease (67.6%; 95% confidence interval (CI) 49.5-82.6) and patients progressing after ET (53.3%; 95% CI 26.6-78.7); as of July 30, 2022, the median progression-free survival with dalpiciclib 150 mg was 24.1 months (95% CI 16.9-46.0) with letrozole/anastrozole and 16.7 months (95% CI 1.9-24.1) with fulvestrant. Conclusion: Dalpiciclib plus letrozole/anastrozole or fulvestrant showed an acceptable safety profile. The recommended phase III dose of dalpiciclib was 150 mg. Trial registration: ClinicalTrials.gov identifier: NCT03481998.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个的应助被卢某某采纳,获得10
刚刚
lucky完成签到 ,获得积分10
1秒前
1秒前
1秒前
JEROME发布了新的文献求助10
2秒前
二旬完成签到 ,获得积分10
2秒前
扣子完成签到 ,获得积分10
3秒前
3秒前
lingxu完成签到 ,获得积分10
3秒前
梨涡完成签到 ,获得积分20
4秒前
子不语完成签到,获得积分10
4秒前
NexusExplorer的应助被张小闲采纳,获得10
4秒前
疯少可还行完成签到,获得积分10
4秒前
学术草履虫完成签到,获得积分10
4秒前
轻松的小笼包完成签到,获得积分10
4秒前
MchemG的应助被weako采纳,获得30
4秒前
潇湘学术完成签到,获得积分0
5秒前
Ava的应助被nuoyefenfei采纳,获得10
5秒前
cullen_zhou完成签到,获得积分10
6秒前
6秒前
姚艳完成签到,获得积分10
6秒前
天天快乐的应助被YPHCC采纳,获得10
7秒前
暖阳完成签到,获得积分10
7秒前
YJT完成签到,获得积分20
8秒前
里工完成签到 ,获得积分10
8秒前
jia完成签到 ,获得积分10
8秒前
科研通AI6.4的应助被xiaomage采纳,获得10
8秒前
是袁三岁完成签到 ,获得积分10
8秒前
知意完成签到,获得积分10
9秒前
9秒前
搬砖民工完成签到,获得积分10
9秒前
乐乐的应助被123采纳,获得10
9秒前
穆礼稀发布了新的文献求助20
9秒前
10秒前
酒酿是也完成签到 ,获得积分10
10秒前
自由山槐的应助被weako采纳,获得30
10秒前
所所的应助被wave8013采纳,获得10
10秒前
adai007发布了新的文献求助10
10秒前
wangs完成签到,获得积分10
10秒前
领导范儿的应助被HK采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570437
关于积分的说明 21812406
捐赠科研通 7776516
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557516
邀请新用户注册赠送积分活动 2479162